Related Experiment Video
Updated: Aug 18, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.0K
Severe pediatric asthma therapy: Dupilumab
Giuliana Ferrante1, Laura Tenero2, Michele Piazza1
1Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Division, University of Verona, Verona, Italy.
Frontiers in Pediatrics
|December 9, 2022
Summary
Dupilumab effectively treats severe pediatric asthma by blocking key inflammatory pathways. Further research is needed to understand its long-term effects and impact on atopy development.
Area of Science:
- Pediatric Pulmonology
- Immunology
- Pharmacology
Background:
- Severe asthma in children is rare but accounts for significant healthcare costs.
- Biological agents, including dupilumab, are emerging treatments for pediatric severe asthma.
- Dupilumab targets the Interleukin (IL)-4 receptor α-subunit, inhibiting IL-4 and IL-13 signaling.
Purpose of the Study:
- To review the efficacy and safety of dupilumab in pediatric severe asthma.
- To discuss current approvals and future research directions for dupilumab in children.
Main Methods:
- Review of recently published randomized controlled trials involving pediatric patients with asthma.
- Analysis of dupilumab's mechanism of action as a monoclonal antibody against IL-4 receptor α-subunit.
Main Results:
- Dupilumab is approved for children with severe asthma and type 2 inflammation uncontrolled by standard therapies.
- Randomized controlled trials have investigated its efficacy and safety in this population.
Conclusions:
- Dupilumab represents a significant advancement in managing severe pediatric asthma.
- Long-term studies are essential to evaluate steroid-sparing effects, treatment discontinuation, and potential impact on childhood atopy.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
411
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
411
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
396
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
396
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:26COPD: Management Using Bronchodilators and Corticosteroids
275
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
275
01:20Asthma: Pathogenesis and Management
512
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
512
01:23Inhaled Medications
357
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
357